Publications by authors named "Yoko Onodera"
Background: Proton pump inhibitors (PPIs) are reported to decrease the efficacy of immune checkpoint inhibitors (ICIs), but there are few reports on the association between ICI efficacy and antacids other than PPIs, and simultaneous examination of the effects of antacids, corticosteroids, and non-steroidal anti-inflammatory drugs (NSAIDs) on ICI therapy.
Methods: We conducted a retrospective study of 381 patients with non-small cell lung cancer who received ICI therapy from January 1, 2016 to December 31, 2022. The primary endpoint was overall survival (OS) and the secondary endpoint was progression-free survival (PFS).
Article Synopsis
- Patients with non-small cell lung cancer (NSCLC) often have driver mutations, like METex14 skipping, which is linked to the effectiveness of MET kinase inhibitors like Tepotinib.
- Tepotinib has a 46% overall response rate and provides a median response duration of 11.1 months, but diagnostic options in Japan are limited mostly to ArcherMET and AmoyDx tests.
- A case study of a 60-year-old man showed that he had a positive METex14 skipping result on the Oncomine Dx test but negative on ArcherMET, highlighting that Tepotinib may still be effective even when other tests yield lower read counts (like 46 in this case).
Article Synopsis
- - The study focuses on the relationship between thromboembolism and BRAF V600E-mutant non-small-cell lung cancer, discovering that nearly half of the patients experienced thrombotic events within a year.
- - Out of 10 patients analyzed, 5 had seven thromboembolic occurrences, including four cancer-related strokes and three venous events, linking early strokes to poor outcomes.
- - The findings suggest that the presence of cancer-related strokes can indicate a worse prognosis for patients with this specific lung cancer mutation.